Clinical Trial Update: Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the contribution of Monophosphoryl Lipid A (MPL) to a grass pollen allergy vaccine has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Grass Pollen Allergy
• Type Hypersensitivity

Drugs mentioned

• MPL-containing grass pollen allergy vaccine

Snippet

Sponsor: Allergy Therapeutics | Conditions: Type I Hypersensitivity | Phase 2 | Status: COMPLETED